Insider · CIK 0001968281
Tariq Musa
director
Files at GH (Guardant Health, Inc.). First filing Dec 16, 2024, latest Dec 19, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $85k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 0Weak | sell10b5-1 | GH Guardant Health, Inc. | $4,043 | 116 | -4% | - | |
| 7Weak | sell 210b5-1 | GH Guardant Health, Inc. | $81k | 2,320 | -46% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | GH Guardant Health, Inc. | SOpen-market sale Common Stock10b5-1 | -116 | $34.85 | $4,043 | 2,810 | Dec 19, 2024 |
| Dec 13, 2024 | GH Guardant Health, Inc. | SOpen-market sale Common Stock10b5-1 | -2,320 | $35.00 | $81k | 2,676 | Dec 16, 2024 |
| Dec 15, 2024 | GH Guardant Health, Inc. | MOption exercise Common Stock10b5-1 | +250 | $0.00 | $0 | 2,926 | Dec 16, 2024 |
| Dec 15, 2024 | GH Guardant Health, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -250 | $0.00 | $0 | 6,746 | Dec 16, 2024 |
| Nov 15, 2024 | GH Guardant Health, Inc. | MOption exercise Common Stock | +250 | $0.00 | $0 | 4,996 | Nov 18, 2024 |
| Nov 15, 2024 | GH Guardant Health, Inc. | MOption exercise Restricted Stock Unitsderivative | -250 | $0.00 | $0 | 6,996 | Nov 18, 2024 |
| Oct 15, 2024 | GH Guardant Health, Inc. | MOption exercise Common Stock | +250 | $0.00 | $0 | 4,746 | Oct 16, 2024 |
| Oct 15, 2024 | GH Guardant Health, Inc. | MOption exercise Restricted Stock Unitsderivative | -250 | $0.00 | $0 | 7,246 | Oct 16, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.